(Q36412132)

14 August 2017

1 reference

title

Recombinant factor VIIa: a review on its clinical use. (English)

1 reference

14 August 2017

1

Massimo Franchini

1 reference

14 August 2017

publication date

1 February 2006

1 reference

International Journal of Hematology

14 August 2017

published in

1 reference

14 August 2017

volume

83

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

126-138

1 reference

https://scigraph.springernature.com/pub.10.1532/ijh97.e0517

14 August 2017

exact match

0 references

cites work

Severe aquired haemophilia A treated with recombinant factor VIIa

1 reference

12 December 2020

Massive pseudotumour resection with recombinant factor VIIa (NovoSeven) cover

1 reference

12 December 2020

Treatment of congenital factor VII deficiency with a new concentrate

1 reference

12 December 2020

The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. A systematic review

1 reference

12 December 2020

Home management of haemophilia.

1 reference

12 December 2020

Use of recombinant factor VIIa in surgery in factor-VII-deficient patients

1 reference

12 December 2020

Recombinant factor VIIa in joint and muscle bleeding episodes

1 reference

12 December 2020

The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency

1 reference

12 December 2020

Treatment of bleeding with recombinant factor VIIa in a patient with extensive burns

1 reference

12 December 2020

Clinical experience with recombinant factor VIIa

1 reference

12 December 2020

Recombinant factor VIIa in preterm neonates with prolonged prothrombin time

1 reference

12 December 2020

Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection

1 reference

12 December 2020

Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients

1 reference

12 December 2020

Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor

1 reference

12 December 2020

Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa

1 reference

12 December 2020

Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy

1 reference

12 December 2020

Experiences with recombinant human factor VIIa in patients with thrombocytopenia

1 reference

12 December 2020

The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.

1 reference

12 December 2020

Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency.

1 reference

12 December 2020

Successful treatment of life-threatening postpartum hemorrhage with recombinant activated factor VII.

1 reference

12 December 2020

Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin

1 reference

12 December 2020

Inhibitors in congenital coagulation disorders

1 reference

12 December 2020

Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII.

1 reference

12 December 2020

Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of recombinant factor VIIa

1 reference

12 December 2020

Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial

1 reference

12 December 2020

Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A.

1 reference

12 December 2020

Successful treatment of intestinal hemorrhage in a Jehovah's Witness patient.

1 reference

12 December 2020

Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets.

1 reference

12 December 2020

NovoSeven in warfarin-treated patients.

1 reference

12 December 2020

Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol.

1 reference

12 December 2020

Effect of recombinant human FVIIA on warfarin-induced bleeding in rats

1 reference

12 December 2020

A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).

1 reference

12 December 2020

The use of recombinant factor VIIa in the treatment of bleeding disorders.

1 reference

12 December 2020

Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects

1 reference

12 December 2020

A cell-based model of coagulation and the role of factor VIIa

1 reference

12 December 2020

Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery

1 reference

12 December 2020

The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor

1 reference

12 December 2020

Acquired haemophilia in association with type III von Willebrand's disease: successful treatment with high purity von Willebrand's factor and recombinant factor VIIa

1 reference

12 December 2020

Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa?

1 reference

12 December 2020

Recombinant activated factor VII for adjunctive hemorrhage control in trauma

1 reference

12 December 2020

A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation

1 reference

12 December 2020

Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia.

1 reference

12 December 2020

The role of recombinant factor VIIa in the treatment of life-threatening haemorrhage in blunt trauma

1 reference

12 December 2020

NovoSeven (recombinant factor VIIa) in centeral nervous systems bleeds

1 reference

12 December 2020

Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia

1 reference

12 December 2020

Factor XI deficiency - from molecular genetics to clinical management

1 reference

12 December 2020

The pharmacokinetics of clotting factor therapy

1 reference

12 December 2020

Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate

1 reference

12 December 2020

Feasibility of using recombinant factor VIIa in continuous infusion.

1 reference

12 December 2020

Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII

1 reference

12 December 2020

Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency

1 reference

12 December 2020

Treatment of traumatic bleeding with recombinant factor VIIa.

1 reference

12 December 2020

Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis.

1 reference

12 December 2020

The use of recombinant factor VIIa in children with inherited platelet function disorders

1 reference

12 December 2020

Confirmation of high dose recombinant factor VIIa in treating patients with Glanzmann thrombasthenia

1 reference

12 December 2020

Overall experience with NovoSeven

1 reference

12 December 2020

Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries

1 reference

12 December 2020

The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0.

1 reference

12 December 2020

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage

1 reference

12 December 2020

Off-label use of recombinant factor VIIa in patients following bone marrow transplantation

1 reference

12 December 2020

Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy

1 reference

12 December 2020

Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures.

1 reference

12 December 2020

Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura

1 reference

12 December 2020

Activated recombinant factor VII for control of diffuse bleeding after implantation of ventricular assist device

1 reference

12 December 2020

Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force

1 reference

12 December 2020

Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: experience of two cases

1 reference

12 December 2020

Factor VII deficiency

1 reference

12 December 2020

Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials

1 reference

12 December 2020

Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency

1 reference

12 December 2020

Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia.

1 reference

12 December 2020

Monitoring coagulation and the clinical effects of recombinant factor VIIa

1 reference

12 December 2020

Early experience with activated recombinant factor VII for intractable hemorrhage after cardiovascular surgery

1 reference

12 December 2020

Recombinant factor VIIa for bleeding in refractory thrombocytopenia

1 reference

12 December 2020

Synthetic factor VIIa to treat dilutional coagulopathy during posterior spinal fusion in two children

1 reference

12 December 2020

The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study

1 reference

12 December 2020

A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa

1 reference

12 December 2020

Recombinant factor VIIa for the management of severe hemorrhages in patients with hematologic malignancies.

1 reference

12 December 2020

Experiences with continuous infusion of recombinant activated factor VII.

1 reference

12 December 2020

The use of recombinant factor viia in a jehovah's witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage

1 reference

12 December 2020

Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention

1 reference

12 December 2020

Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.

1 reference

12 December 2020

Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia

1 reference

12 December 2020

Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa

1 reference

12 December 2020

Coagulation problems in liver disease

1 reference

12 December 2020

Views on methods for monitoring recombinant factor VIIa in inhibitor patients

1 reference

12 December 2020

Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study.

1 reference

12 December 2020

Pharmacokinetics of recombinant activated factor VII (rFVIIa).

1 reference

12 December 2020

Recombinant factor VIIa (NovoSeven) as a hemostatic agent

1 reference

12 December 2020

Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review

1 reference

12 December 2020

Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors

1 reference

12 December 2020

Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies

1 reference

12 December 2020

Continuous infusion of recombinant factor VIIa: continue or not?

1 reference

12 December 2020

Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity

1 reference

12 December 2020

An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII

1 reference

12 December 2020

Literature review of surgery management in inhibitor patients

1 reference

12 December 2020

Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma.

1 reference

12 December 2020

Inhibitor treatment: state of the art

1 reference

12 December 2020

Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program

1 reference

12 December 2020

How factor VIIa works in hemophilia

1 reference

12 December 2020

Clinical heterogeneity of acquired hemophilia A: a description of 4 cases.

1 reference

12 December 2020

Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.

1 reference

12 December 2020

Treatment of factor XI inhibitor using recombinant activated factor VIIa

1 reference

12 December 2020

Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia

1 reference

12 December 2020

Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial.

1 reference

12 December 2020

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.

1 reference

12 December 2020

Successful use of recombinant factor VIIa for emergency fasciotomy in a patient with hemophilia A and high-titer inhibitor unresponsive to factor VIII inhibitor bypassing activity

1 reference

12 December 2020

Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?

1 reference

12 December 2020

Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VII

1 reference

12 December 2020

Treatment of bleeding in severe necrotizing pancreatitis with recombinant factor VIIa

1 reference

12 December 2020

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors

1 reference

12 December 2020

Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa.

1 reference

12 December 2020

Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa

1 reference

12 December 2020

Potential role for rFVIIa in transfusion medicine

1 reference

12 December 2020

Recombinant FVIIa in the management of uncontrolled hemorrhage

1 reference

12 December 2020

A cell-based model of hemostasis

1 reference

12 December 2020

Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders.

1 reference

12 December 2020

Severe gastrointestinal haemorrhage responding to recombinant factor VIIa in a Jehovah's Witness with refractory immune thrombocytopenia

1 reference

12 December 2020

Blood coagulation in hemophilia A and hemophilia C.

1 reference

12 December 2020

Splenic embolization in a Jehovah's Witness: role of recombinant human factor VIIa

1 reference

12 December 2020

Safety profile of recombinant factor VIIa

1 reference

12 December 2020

Successful use of recombinant FVIIa (Novoseven) in the management of intractable post-surgical intra-abdominal haemorrhage

1 reference

12 December 2020

Transfusion medicine service policies for recombinant factor VIIa administration

1 reference

12 December 2020

Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.

1 reference

12 December 2020

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia

1 reference

12 December 2020

Recombinant-activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices

1 reference

12 December 2020

Surgery in haemophilic patients with inhibitor: 20 years of experience.

1 reference

12 December 2020

New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate

1 reference

12 December 2020

Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage.

1 reference

12 December 2020

Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy

1 reference

12 December 2020

Platelet activity of high-dose factor VIIa is independent of tissue factor

1 reference

12 December 2020

Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study

1 reference

12 December 2020

The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications

1 reference

12 December 2020

Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor.

1 reference

12 December 2020

Clinical use of recombinant FVIIa (rFVIIa).

1 reference

12 December 2020

NovoSeven: mode of action and use in acquired haemophilia

1 reference

12 December 2020

Factor VIIa in the treatment of haemophilia.

1 reference

12 December 2020

Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors

1 reference

12 December 2020

The concept of recombinant factor VIIa megadose for treating bleeding episodes in high-titer inhibitor patients with hemophilia: toward an expanding indication?

1 reference

12 December 2020

Thrombosis and recombinant factor VIIa

1 reference

12 December 2020

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group

1 reference

12 December 2020

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

1 reference

12 December 2020

Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation

1 reference

12 December 2020

Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures

1 reference

12 December 2020

Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium

1 reference

12 December 2020

Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding

1 reference

12 December 2020

Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery.

1 reference

12 December 2020

Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery

1 reference

12 December 2020

Recombinant factor VIIa in the management of a pseudotumour in acquired haemophilia

1 reference

12 December 2020

Experience with continuous infusion of recombinant activated factor VII in the Asia-Pacific region

1 reference

12 December 2020

The use of recombinant factor VIIa (NovoSeven) in a patient with a factor XI deficiency and a circulating anticoagulant

1 reference

12 December 2020

High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system.

1 reference

12 December 2020

Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.

1 reference

12 December 2020

Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa

1 reference

12 December 2020

Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency

1 reference

12 December 2020

Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding

1 reference

12 December 2020

Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device

1 reference

12 December 2020

Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage.

1 reference

12 December 2020

A factor VII concentrate for therapeutic use

1 reference

12 December 2020

Home treatment with recombinant activated factor VII: results from one centre.

1 reference

12 December 2020

Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor

1 reference

12 December 2020

Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development

1 reference

12 December 2020

Prolonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: case report and review of the literature

1 reference

12 December 2020

1 reference

12 December 2020

Mechanism of action of recombinant factor VIIa

1 reference

12 December 2020

Successful control of massive coumarol-induced acute upper gastrointestinal bleeding and correction of prothrombin time by recombinant active factor VII (Eptacog-alpha, NovoSeven) in a patient with a prosthetic aortic valve and two malignancies (chr

1 reference

12 December 2020

Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review

1 reference

12 December 2020

Control of bleeding in patients with haemophilia A with inhibitors: a systematic review

1 reference

12 December 2020

Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices

1 reference

12 December 2020

Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis

1 reference

12 December 2020

Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group.

1 reference

12 December 2020

Recombinant activated factor VII for non-hemophiliac bleeding patients

1 reference

12 December 2020

Successful short-term oral surgery prophylaxis with rFVIIa in severe congenital factor VII deficiency

1 reference

12 December 2020

Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey.

1 reference

12 December 2020

Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial

1 reference

12 December 2020

Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency

1 reference

12 December 2020

Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia

1 reference

12 December 2020

Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven).

1 reference

12 December 2020

Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor

1 reference

12 December 2020

Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy

1 reference

12 December 2020

Prophylactic effect of recombinant factor VIIa in factor VII deficient patients.

1 reference

12 December 2020

Control of life-threatening pulmonary bleeding with activated recombinant factor VII

1 reference

12 December 2020

Analysis and results of the recombinant factor VIIa extended-use registry

1 reference

12 December 2020

Experience with recombinant factor VIIa in Australia and New Zealand

1 reference

12 December 2020

Recombinant activated factor VII for acute intracerebral hemorrhage.

1 reference

12 December 2020

Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count

1 reference

12 December 2020

Recombinant factor VIIa in severe uremic bleeding

1 reference

12 December 2020

Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease

1 reference

12 December 2020

Severe acquired hemophilia A successfully treated with activated recombinant human factor VII.

1 reference

12 December 2020

Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa

1 reference

12 December 2020

Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII

1 reference

12 December 2020

"Off-license" use of recombinant activated factor VII.

1 reference

12 December 2020

Identifiers

DOI

10.1532/IJH97.E0517

1 reference

Dimensions Publication ID

14 August 2017

1052224262

0 references

1 reference